RYTM Relative Valuation
RYTM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RYTM is overvalued; if below, it's undervalued.
Historical Valuation
Rhythm Pharmaceuticals Inc (RYTM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 30.20 is considered Overvalued compared with the five-year average of -11.33. The fair price of Rhythm Pharmaceuticals Inc (RYTM) is between 48.81 to 62.37 according to relative valuation methord. Compared to the current price of 88.57 USD , Rhythm Pharmaceuticals Inc is Overvalued By 42.01%.
Relative Value
Fair Zone
48.81-62.37
Current Price：88.57
42.01%
Overvalued
-33.02
PE
1Y
3Y
5Y
Trailing
Forward
-38.37
EV/EBITDA
Rhythm Pharmaceuticals Inc. (RYTM) has a current EV/EBITDA of -38.37. The 5-year average EV/EBITDA is -8.22. The thresholds are as follows: Strongly Undervalued below -22.76, Undervalued between -22.76 and -15.49, Fairly Valued between -0.95 and -15.49, Overvalued between -0.95 and 6.32, and Strongly Overvalued above 6.32. The current Forward EV/EBITDA of -38.37 falls within the Strongly Undervalued range.
-37.58
EV/EBIT
Rhythm Pharmaceuticals Inc. (RYTM) has a current EV/EBIT of -37.58. The 5-year average EV/EBIT is -9.01. The thresholds are as follows: Strongly Undervalued below -24.22, Undervalued between -24.22 and -16.62, Fairly Valued between -1.41 and -16.62, Overvalued between -1.41 and 6.19, and Strongly Overvalued above 6.19. The current Forward EV/EBIT of -37.58 falls within the Strongly Undervalued range.
30.20
PS
Rhythm Pharmaceuticals Inc. (RYTM) has a current PS of 30.20. The 5-year average PS is 50.62. The thresholds are as follows: Strongly Undervalued below -142.25, Undervalued between -142.25 and -45.81, Fairly Valued between 147.05 and -45.81, Overvalued between 147.05 and 243.48, and Strongly Overvalued above 243.48. The current Forward PS of 30.20 falls within the Historic Trend Line -Fairly Valued range.
-47.49
P/OCF
Rhythm Pharmaceuticals Inc. (RYTM) has a current P/OCF of -47.49. The 5-year average P/OCF is -13.17. The thresholds are as follows: Strongly Undervalued below -40.18, Undervalued between -40.18 and -26.67, Fairly Valued between 0.34 and -26.67, Overvalued between 0.34 and 13.84, and Strongly Overvalued above 13.84. The current Forward P/OCF of -47.49 falls within the Strongly Undervalued range.
-37.55
P/FCF
Rhythm Pharmaceuticals Inc. (RYTM) has a current P/FCF of -37.55. The 5-year average P/FCF is -9.56. The thresholds are as follows: Strongly Undervalued below -23.22, Undervalued between -23.22 and -16.39, Fairly Valued between -2.73 and -16.39, Overvalued between -2.73 and 4.09, and Strongly Overvalued above 4.09. The current Forward P/FCF of -37.55 falls within the Strongly Undervalued range.
Rhythm Pharmaceuticals Inc (RYTM) has a current Price-to-Book (P/B) ratio of 302.41. Compared to its 3-year average P/B ratio of 77.31 , the current P/B ratio is approximately 291.18% higher. Relative to its 5-year average P/B ratio of 47.35, the current P/B ratio is about 538.66% higher. Rhythm Pharmaceuticals Inc (RYTM) has a Forward Free Cash Flow (FCF) yield of approximately -1.91%. Compared to its 3-year average FCF yield of -8.11%, the current FCF yield is approximately -76.38% lower. Relative to its 5-year average FCF yield of -15.04% , the current FCF yield is about -87.27% lower.
302.41
P/B
Median3y
77.31
Median5y
47.35
-1.91
FCF Yield
Median3y
-8.11
Median5y
-15.04
Competitors Valuation Multiple
The average P/S ratio for RYTM's competitors is 8.92, providing a benchmark for relative valuation. Rhythm Pharmaceuticals Inc Corp (RYTM) exhibits a P/S ratio of 30.20, which is 238.61% above the industry average. Given its robust revenue growth of 25.94%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RYTM increased by 90.82% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -13.50 to -32.01.
The secondary factor is the Revenue Growth, contributed 25.94%to the performance.
Overall, the performance of RYTM in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Rhythm Pharmaceuticals Inc (RYTM) currently overvalued or undervalued?
What is Rhythm Pharmaceuticals Inc (RYTM) fair value?
How does RYTM's valuation metrics compare to the industry average?
What is the current P/B ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Aug 06 2025?
What is the current FCF Yield for Rhythm Pharmaceuticals Inc (RYTM) as of Aug 06 2025?
What is the current Forward P/E ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Aug 06 2025?